Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Articles /     
 
Producer responds to FDA recall of ProHeart 6
Fort Dodge Animal, the producer of the milbemycin containing Proheart® 6, says it will voluntarily comply with the recent FDA’s request to recall Proheart® 6, the only injectable heartworm preventive on the market. Currently, the reasons for many of the sometimes fatal side effects of the product remain unclear.


The Food and Drug Administration (FDA) will create an independent advisory panel to further investigate the numbers of adverse reactions associated with the product before the product can be marketed again.

The company says it has “concerns about how the agency interpreted these complex data.” The company adds in a prepared statement that it “fully supports the initiation of this review process, and will work closely with FDA to provide any necessary information for the panel to make a fair and accurate assessment of these data.” Fort Dodge stands behind the safety of its product.

Dr. Stephen Sundlof, director of FDA’s Center for Veterinary Medicine, says, “This was the first product administered once every six months, which has some good advantages for compliance. We are started seeing some adverse reactions that we did not see in the preclinical studies.”

“We don’t understand why this drug is causing some of these problems,” Sundlof says. `Until we can understand that better and develop ways to reduce adverse events, we thought it is important to not expose any more dogs to this product.”

Source: DVM Newsmagazine Sep 8, 2004; www.dvmnewsmagazine.com/dvm/



Tell a friend   |   Print version   |   Send this article

ARTICLES

Pharmacokinetics of quinocetone in ducks after two routes of administrationmembers
Quinocetone (QCT), an antimicrobial growth promoter, is widely used in food-producing animals. However, information about pharmacokinetics (PK) of QCT in ducks still remains unavailable up to now. In this study, QCT and its major metabolites (1-desoxyquinocetone, di-desoxyquinocetone and 3-methyl-quinoxaline-2-carboxylic) in ducks were studied using a simple and sensitive UHPLC-MS/MS assay.

  • Novel antibiotic treatment of zebrafish mycobacteriosismembers
  • Canine mammary tumours as model for hereditary breast cancer susceptibility genes in humansmembers
  • Treatment of corneal ulceration in stranded California sea lions members
  • Effects of substrates and stress on placental metabolismmembers
  • Vaccine regimens against caecal Salmonella Typhimurium colonisation in laying hensmembers
  • Presumptive keratoglobus in a raptormembers
  • Monitored, controlled long-term anaesthesia in broiler chickenmembers
  • Pharmacokinetics of cefovecin in alpacasmembers
  • Use and effect of hand antiseptics in veterinary practicemembers
  • Two dogs with cold agglutinin activitymembers
  • Mechanical ventilation and blood gases and blood pressure in rattlesnakesmembers
  • Infectious haemolytic anemia in an orphaned juvenile female platypus members


  • [ Home ] [ About ] [ Contact / Request ][ Disclaimer ]

    Copyright © 2001-2016 VetContact GmbH
    All rights reserved